

2024



NUCLEIC ACID INSIGHTS

EDITORIAL CALENDAR

Special Editions	Monthly content focus	JANUARY	FEBRUARY	MARCH	APRIL	MAY	JUNE
			Special Launch Issue (see page 2 for details)	Delivery & Formulation		mRNA Processing & Analysis	
					mRNA: Processing		mRNA: Engineering and design
					Oligonucleotides: Targeting & delivery		Oligonucleotides: Analytics & CMC
					pDNA: Analytics & CMC		pDNA: Supply chain
Special Editions	Monthly content focus	JULY	AUGUST	SEPTEMBER	OCTOBER	NOVEMBER	DECEMBER
				Oligonucleotide Manufacture & Supply Chain			Plasmid DNA
		mRNA: Preclinical & translational tools	mRNA: Clinical development strategy		mRNA: Processing	mRNA: Analytics & CMC	
		Oligonucleotides: Clinical development strategy	Oligonucleotides: Emerging modalities		Oligonucleotides: Conjugated oligos	Oligonucleotides: Research, preclinical and translational R&D strategy	
		pDNA: Analytics & CMC	pDNA: Processing		pDNA: Next-generation technologies	pDNA: Regulation	
		Formulation & delivery: Guide RNA innovation	Formulation & delivery: Extracellular vesicles		Formulation & delivery: LNPs	Formulation & delivery: RNA/DNA delivery of genome editing platforms	

Contact Nicola McCall on +44 1732 463215 or n.mccall@insights.bio to discuss thought leadership and lead generation opportunities

2024

EDITORIAL CALENDAR

Spotlights summary

JANUARY

FEBRUARY

MARCH

Delivery & Formulation

Contributors include:
Dr Naim Nazef, Takeda; **Dr Yupeng Chen**, University of Connecticut; **Professor Colin Pouton** and **Dr Angus Johnston**, Monash University; **Nizar Saad**, Assistant Professor, Ohio State University

APRIL

MAY

JUNE

mRNA Processing & Analysis

Contributors include:
Dr Peter Oliver, Nucleic Acid Therapy Accelerator (NATA) and University of Oxford; **Dr Sritama Bose**, NATA; **Dr Merle Fuchs**, PRAMOMOLECULAR; **Dr Julien Couture-Senecal**, Azane Therapeutics; **Alexander Aust**, Aust Business Solutions

Contributors include:
Dr Andrew Varley, The University of British Columbia; **Francis Galaway**, UK MHRA; **Ariel Weinberger** and **Timothy Notton**, Autonomous Therapeutics

Contributors include:
Rachel Groppo, Janssen Pharmaceuticals; **Jeske Smink**, Silence Therapeutics; **Husain Atterwala**, Aera Therapeutics

JULY

AUGUST

SEPTEMBER

Innovation in Oligonucleotide Manufacture & Supply Chain

OCTOBER

NOVEMBER

DECEMBER

Plasmid DNA

Contributors include:
Dr John Li, Capstan Therapeutics; **Bill Grier**, Omega Therapeutics; **Rui Zhang**, Stylus Medicine

Contributors include:
Michelle Berg, Independent Consultant (formerly Aldevron); **Dr David Öling**, AstraZeneca

NUCLEIC ACID INSIGHTS SPECIAL LAUNCH EDITION FEBRUARY 2024

The inaugural edition of *Nucleic Acid Insights* features a wide variety of stakeholders from across the nucleic acids space sharing their perspectives on recent progress, current challenges, and future directions in the field.

Confirmed contributors to this special edition include:

Floris Engelhardt, CEO, Kano Therapeutics
Jane A. Healy, VP, Head of Oncology Early Clinical Development, Merck & Co, Inc.
Robert Langer, David H. Koch Institute Professor, MIT
John Lewis, CEO, Entos Pharmaceuticals
Paolo Martini, CSO, International Therapeutics Research Centers, Founder of Moderna Rare Diseases, Moderna
Chris Mason, Professor of Cell and Gene Therapy, Advanced Centre for Biochemical Engineering, University College London
Myriam Mendila, Chief Development Officer, Curevac
Matthew Scholz, CEO, Oisín Biotechnologies
Hartaj Singh, Managing Director, Oppenheimer & Co. Inc.

Contact Nicola McCall on +44 1732 463215 or n.mccall@insights.bio to discuss thought leadership and lead generation opportunities

2024

EDITORIAL CALENDAR

Spotlight details

Nucleic Acid Insights' Spotlights provide you with fantastic opportunities to:

- Educate your target market** about your company's expertise, capabilities and experience
- Share your latest data** with organisations looking for partners and service providers in your field
- Profile your executives and scientists** as thought-leaders and KOLs
- Generate qualified leads** from across the global sector
- Increase awareness** of your company's role in cell and gene therapy R&D and manufacture.

Each spotlight will comprise:

- Peer-reviewed Reviews and Expert Insight articles** written by leading experts in the field
- Webinars**, featuring industry speakers and sponsors discussing key topics specific to the Spotlight
- Podcast, written and video interviews** with key opinion leaders
- On demand **roundtable discussions**

MAR

Delivery & Formulation

- ▶ Tissue-specific targeting – which approaches are proving to be optimal?
 - ▶ How and where can we move beyond the liver ?
- ▶ Nanoparticles (lipid and polymer)
 - ▶ Overcoming freedom to operate barriers
- ▶ Extracellular vesicles
- ▶ Chemical conjugates
- ▶ Exploring novel techniques for oligonucleotide formulation / encapsulation
- ▶ Optimizing RNA stability
- ▶ Addressing toxicity issues in DNA delivery
- ▶ Advancing non-temperature-dependent formulation

MAY

mRNA Processing & Analysis

- ▶ How to reduce CoGs?
- ▶ Process optimization
 - ▶ How to drive improvements in scalability and consistency?
 - ▶ What are advances in mRNA manufacturing automation and the application of single-use technologies delivering in practice?
 - ▶ How best to address potential downstream purification issues in upstream processing?
 - ▶ Needs and opportunities in downstream processing
- ▶ Analytical innovation: recent breakthroughs and remaining needs

SEP

Innovation in Oligonucleotide Manufacture & Supply Chain

- ▶ How to address the growing shortfall in supply of GMP-grade synthesized oligos?
- ▶ What progress in enhancing capabilities while controlling costs in oligo synthesis?
- ▶ How to improve the sustainability of oligo manufacturing?

DEC

Plasmid DNA

- ▶ How to address the ongoing supply bottleneck?
 - ▶ Improving and accelerating plasmid manufacturing processes
- ▶ How great a threat do synthetic approaches really present to pDNA?
- ▶ Improving pDNA processing productivity, quality, consistency, and cost effectiveness
 - ▶ Single-use systems
 - ▶ What are the 'must-do's' to ensure pDNA quality (both for use as a starting material and as a drug product)?